D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 109 Citations 57,574 406 World Ranking 3325 National Ranking 1888

Overview

What is he best known for?

The fields of study Christopher L. Corless is best known for:

  • Cancer
  • Gene
  • Chemotherapy

With his scientific publications, his incorporates both Cancer research and Melanoma. He connects Melanoma with Cancer research in his research. His research on Myeloid leukemia frequently links to adjacent areas such as Imatinib mesylate. His research on Imatinib mesylate often connects related topics like Myeloid leukemia. He performs integrative study on Imatinib and Targeted therapy. In his research, Christopher L. Corless undertakes multidisciplinary study on Targeted therapy and Imatinib. His Stromal cell study frequently draws parallels with other fields, such as Stromal tumor. His Pathology research extends to the thematically linked field of Stromal tumor. His PDGFRA research extends to the thematically linked field of Pathology.

His most cited work include:

  • PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors (2074 citations)
  • Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (2059 citations)
  • Biology of Gastrointestinal Stromal Tumors (1064 citations)

What are the main themes of his work throughout his whole career to date

Internal medicine and Surgery are two areas of study in which Christopher L. Corless engages in interdisciplinary research. He merges Surgery with Internal medicine in his study. He integrates Cancer research with Oncology in his study. He incorporates Oncology and Cancer research in his studies. With his scientific publications, his incorporates both Pathology and Immunohistochemistry. He performs multidisciplinary studies into Immunohistochemistry and Pathology in his work. His study in Stem cell extends to Genetics with its themes. His Stem cell study frequently intersects with other fields, such as Genetics. While working on this project, Christopher L. Corless studies both Cancer and Myeloid leukemia.

Christopher L. Corless most often published in these fields:

  • Internal medicine (60.00%)
  • Cancer research (49.09%)
  • Pathology (47.73%)

What were the highlights of his more recent work (between 2015-2022)?

  • Cancer (65.52%)
  • Genetics (58.62%)
  • Internal medicine (55.17%)

In recent works Christopher L. Corless was focusing on the following fields of study:

Christopher L. Corless performs multidisciplinary study in the fields of Cancer and Immunohistochemistry via his papers. His Immunohistochemistry study frequently draws parallels with other fields, such as Internal medicine. As part of his studies on Internal medicine, he often connects relevant areas like Metastasis. Christopher L. Corless merges Metastasis with Cancer in his research. His research on Genetics often connects related topics like Fibrosarcoma. The study of Fibrosarcoma is intertwined with the study of Genetics in a number of ways. Gene and Chromosome are two areas of study in which Christopher L. Corless engages in interdisciplinary research. He undertakes interdisciplinary study in the fields of Chromosome and Gene through his works. His work on Pathology is being expanded to include thematically relevant topics such as Sarcoma.

Between 2015 and 2022, his most popular works were:

  • FGFR1 and NTRK3 actionable alterations in “Wild-Type” gastrointestinal stromal tumors (144 citations)
  • Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results (65 citations)
  • Durable Response to Afatinib in Lung Adenocarcinoma Harboring NRG1 Gene Fusions (52 citations)

In his most recent research, the most cited works focused on:

  • Cancer
  • Gene
  • Mutation

His work on Lung expands to the thematically related Internal medicine. His study connects Internal medicine and Lung. His multidisciplinary approach integrates Cancer and Adenocarcinoma in his work. His Genetics study frequently links to adjacent areas such as Mesenchymal stem cell. Christopher L. Corless integrates Mesenchymal stem cell and Stem cell in his research. The study of Stem cell is intertwined with the study of CD34 in a number of ways. In his works, Christopher L. Corless undertakes multidisciplinary study on Pathology and Precision medicine. Christopher L. Corless undertakes interdisciplinary study in the fields of Oncology and Gastroenterology through his works. Christopher L. Corless integrates Gastroenterology with Oncology in his research.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

George Daniel Demetri;Margaret von Mehren;Charles D. Blanke;Annick Diane Van Den Abbeele.
The New England Journal of Medicine (2002)

5237 Citations

Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Christopher D.M. Fletcher;Jules J. Berman;Christopher Corless;Fred Gorstein.
Human Pathology (2002)

4443 Citations

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

Michael C. Heinrich;Christopher L. Corless;Anette Duensing;Laura McGreevey.
Science (2003)

2860 Citations

Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor

Michael C. Heinrich;Christopher L. Corless;George D. Demetri;Charles D. Blanke.
Journal of Clinical Oncology (2003)

2703 Citations

Biology of gastrointestinal stromal tumors.

Christopher L. Corless;Jonathan A. Fletcher;Michael C. Heinrich.
Journal of Clinical Oncology (2004)

1559 Citations

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

Charles D Blanke;George D Demetri;Margaret von Mehren;Michael C Heinrich.
Journal of Clinical Oncology (2008)

1240 Citations

NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines.

George D. Demetri;Robert S. Benjamin;Charles D. Blanke;Jean Yves Blay.
Journal of The National Comprehensive Cancer Network (2007)

1036 Citations

PDGFRA Mutations in Gastrointestinal Stromal Tumors: Frequency, Spectrum and In Vitro Sensitivity to Imatinib

Christopher L. Corless;Arin Schroeder;Diana Griffith;Ajia Town.
Journal of Clinical Oncology (2005)

994 Citations

Consensus meeting for the management of gastrointestinal stromal tumors Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO

Jean Yves Blay;Sylvie Bonvalot;Paolo Casali;Haesun Choi.
Annals of Oncology (2005)

994 Citations

Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors

Michael C. Heinrich;Christopher L. Corless;Charles D. Blanke;George D. Demetri.
Journal of Clinical Oncology (2006)

952 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Christopher L. Corless

Jean-Yves Blay

Jean-Yves Blay

Claude Bernard University Lyon 1

Publications: 128

Cristina R. Antonescu

Cristina R. Antonescu

Memorial Sloan Kettering Cancer Center

Publications: 104

George D. Demetri

George D. Demetri

Harvard University

Publications: 94

Jonathan A. Fletcher

Jonathan A. Fletcher

Brigham and Women's Hospital

Publications: 92

Robert G. Maki

Robert G. Maki

University of Pennsylvania

Publications: 86

Ronald P. DeMatteo

Ronald P. DeMatteo

University of Pennsylvania

Publications: 86

Heikki Joensuu

Heikki Joensuu

University of Helsinki

Publications: 80

Alessandro Gronchi

Alessandro Gronchi

University of Milan

Publications: 78

Paolo G. Casali

Paolo G. Casali

University of Milan

Publications: 78

Peter Hohenberger

Peter Hohenberger

Heidelberg University

Publications: 77

Piotr Rutkowski

Piotr Rutkowski

Maria Sklodowska-Curie National Research Institute of Oncology

Publications: 77

Jason L. Hornick

Jason L. Hornick

Brigham and Women's Hospital

Publications: 74

Axel Le Cesne

Axel Le Cesne

Institut Gustave Roussy

Publications: 66

Michael Heinrich

Michael Heinrich

Oregon Health & Science University

Publications: 65

Alexander J. Lazar

Alexander J. Lazar

The University of Texas MD Anderson Cancer Center

Publications: 64

Markku Miettinen

Markku Miettinen

National Cancer Institute

Publications: 62

Trending Scientists

Thomas G. Sugar

Thomas G. Sugar

Arizona State University

Carol A. Fierke

Carol A. Fierke

Texas A&M University

Deborah L. Zink

Deborah L. Zink

Justus-Liebig university of Giessen

Kang Choon Lee

Kang Choon Lee

Sungkyunkwan University

Xiaolin Wei

Xiaolin Wei

Xiangtan University

Carsten Sönnichsen

Carsten Sönnichsen

Johannes Gutenberg University of Mainz

Gregory Starr

Gregory Starr

University of Alabama

Aleš Svatoš

Aleš Svatoš

Max Planck Society

David W. Rose

David W. Rose

University of California, San Diego

Kevin P. Gallo

Kevin P. Gallo

National Oceanic and Atmospheric Administration

Ramachandran Ramesh

Ramachandran Ramesh

Ministry of Environment, Forests and Climate Change

Sang Kun Lee

Sang Kun Lee

Seoul National University Hospital

R. Douglas Fields

R. Douglas Fields

National Institutes of Health

Crystal L. Mackall

Crystal L. Mackall

Stanford University

Peter R. Carroll

Peter R. Carroll

University of California, San Francisco

Rolf D. Hubmayr

Rolf D. Hubmayr

Mayo Clinic

Something went wrong. Please try again later.